LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

LLY

769.87

-0.02%↓

UNH

524.65

+0.64%↑

NVO

131.87

-0.86%↓

MRK

131.21

+0.28%↑

ABBV

166.41

+1.24%↑

Home・Stock List・Johnson and Johnson

Johnson and Johnson

Open

Sector Healthcare

154.71 0.26

Buy Sell

Overview

Share price change

24h

Current

Min

154.28

Max

154.73

Key metrics
By Trading Economics
Income	-22B 4B
Sales	-15M 21B
P/E Sector Avg	32.629 23.904
EPS	2.71
Dividend yield	2.876
Profit margin	18.925
Employees	131,900
EBITDA	-386M 6.5B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+12.52 upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.88% 7.76%
Next Earnings	18 Jul 2024
Next Dividend date	4 Jun 2024
Next Ex Dividend date	20 May 2024

Market Stats
By TradingEconomics
Market Cap	4.7B 369B
Previous open	154.45
Previous close	154.71

News Sentiment

By Acuity

31%

69%

58 / 368 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

149.89 / N/A Support & Resistance

Johnson and Johnson Chart

Related News

16 May 2024, 12:07 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio

13 May 2024, 14:06 UTC

Acquisitions, Mergers, Takeovers

J&J to Sell Remaining Stake in Kenvue Spinoff

29 Apr 2024, 11:37 UTC

Major Market Movers

Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure

24 Apr 2024, 23:16 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset

16 Apr 2024, 14:06 UTC

Earnings

Trending: Johnson & Johnson 1Q Adjust Earnings Beat Forecasts as Company Raises Dividend

16 Apr 2024, 11:01 UTC

Earnings

Johnson & Johnson 1Q Sales Rise on U.S. Growth, Narrows Adjusted EPS Outlook

17 May 2024, 03:56 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Deal for Biotechnology Co Proteologix Includes Potential for Additional Milestone Payment

17 May 2024, 03:49 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Agrees to Acquire Proteologix for $850M in Cash >JNJ

17 May 2024, 03:47 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Proteologix >JNJ

16 May 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Proteologix's Portfolio Includes PX128, a Bispecific Antibody Targeting IL-13 Plus TSLP >JNJ

16 May 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Acquisition Advances Dermatology Portfolio With Opportunity to Address Significant Unmet Need in Atopic Dermatitis >JNJ

16 May 2024, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Proteologix for $850M in Cash, With Potential for Additonal Milestone Payments >JNJ

16 May 2024, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Acquire Proteologix, Inc. To Lead In Atopic Dermatitis Treatment >JNJ

16 Apr 2024, 13:39 UTC

Hot Stocks

Stocks to Watch Tuesday: UnitedHealth, Tesla, J&J, Live Nation -- WSJ

16 Apr 2024, 12:57 UTC

Earnings

Bellwether Health Giant J&J Beats Earnings Calls, But Shares Dip On Light Sales -- IBD

16 Apr 2024, 11:13 UTC

Market Talk

Johnson & Johnson Extends Dividend Royalty -- Market Talk

16 Apr 2024, 10:32 UTC

Earnings

Johnson & Johnon's Q1 Profit Beats As Sales Fall Slightly Short Of Estimates -- MarketWatch

16 Apr 2024, 10:24 UTC

Earnings

Johnson & Johnson 1Q Adjusted Operational Sales Growth Excluding Covid-19 Vaccine 7.7% >JNJ

16 Apr 2024, 10:23 UTC

Earnings

Johnson & Johnson Raises Low Ends of 2024 Adjusted Operational EPS, Sales Growth Views >JNJ

16 Apr 2024, 10:23 UTC

Earnings

Johnson & Johnson Raises 2024 Operational Sales View to $88.7B-$89.1B >JNJ

16 Apr 2024, 10:22 UTC

Earnings

Johnson & Johnson Narrows 2024 Adjusted Operational Sales Growth View to 5.5%-6% >JNJ

16 Apr 2024, 10:22 UTC

Earnings

Johnson & Johnson Narrows 2024 Adjusted Operational EPS View to $10.60-$10.75 >JNJ

16 Apr 2024, 10:21 UTC

Earnings

Johnson & Johnson Narrows 2024 View To Adj EPS $10.57-Adj EPS $10.72 >JNJ

16 Apr 2024, 10:21 UTC

Earnings

Johnson & Johnson Narrows 2024 View To Sales $88B-$88.4B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q EPS $2.20 >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q U.S. Sales $11.62B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q Worldwide MedTech Sales $7.82B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q International Sales $9.76B >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q Adj EPS $2.71 >JNJ

16 Apr 2024, 10:20 UTC

Earnings

Johnson & Johnson 1Q Net $5.35B >JNJ

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

12.52% upside

12 Months Forecast

Average 174 USD 12.52%

High 215 USD

Low 155 USD

Based on 13 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Technical Score

By Trading Central

149.89 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

58 / 368 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.